Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies

Palmoplantar pustulosis (PPP) is a chronic, relapsing, inflammatory disease that can occur alone or in association with arthritis. There is still controversy about whether it should be separated from psoriasis or classified as pustular psoriasis. Furthermore, drug-induced paradoxical PPP is a specia...

Full description

Saved in:
Bibliographic Details
Published inPsoriasis (Auckland, New Zealand) Vol. 13; pp. 33 - 58
Main Authors Heidemeyer, Kristine, Lee, Marco May, Cazzaniga, Simone, Yawalkar, Nikhil, Naldi, Luigi
Format Journal Article
LanguageEnglish
Published Dove Medical Press Limited 30.09.2023
Dove
Dove Medical Press
Subjects
Alefacept
Alitretinoin
Antiarthritic agents
Arthritis
Development and progression
Fumaric acid
Monoclonal antibodies
palmoplantar
Phototherapy
Psoriasis
Public-private sector cooperation
pustulosis
Review
risk factors
Smokers
Thyroid diseases
treatment
Tumor necrosis factor
Japan
Online AccessGet full text

Cover

More Information
Summary:Palmoplantar pustulosis (PPP) is a chronic, relapsing, inflammatory disease that can occur alone or in association with arthritis. There is still controversy about whether it should be separated from psoriasis or classified as pustular psoriasis. Furthermore, drug-induced paradoxical PPP is a special variant of PPP that differs from classic PPP in several ways. Treatment of PPP is still challenging, and there are a number of treatment-resistant cases. This review summarizes the risk factors for the development of PPP and the currently available treatment modalities. Female sex, smokers or ex-smokers, obesity, thyroid dysfunction, and treatment with a tumor necrosis factor (TNF)-[alpha] inhibitor have been identified as risk factors for the disease's development, severity, and course. Topical treatments and phototherapy are effective for some patients and are used as a first-line or adjuvant treatment modality. Conventional treatments including retinoids and fumaric acid show good effects and can increase the efficacy of treatment with psoralen + ultraviolet light therapy (PUVA). Ciclosporin is fast acting, but relapse mostly occurs immediately after cessation. TNF-[alpha] inhibitors are efficient, and an even better response can be achieved with IL-17 and IL-23 blockers as well as apremilast. The effect of Janus kinase inhibitors seems to be promising according to case reports, but further investigations with larger cohorts are needed. Keywords: palmoplantar, pustulosis, psoriasis, treatment, risk factors
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2230-326X
2230-326X
DOI:10.2147/PTT.S400402